bioMérieux – First-Quarter 2016 Business Review

• Solid growth in sales, up 11.5% at constant exchange rates and scope of consolidation
• €489 million in sales
• Up 9.1% as reported
• Americas (up 22.5%) confirms its role as a key growth driver for the Group
• Clinical microbiology: up 6.7%, driven primarily by successful sales of the VITEK® and BacT/ALERT® lines
• FilmArray® Torch high-throughput system CE marked and FDA cleared with all four existing FilmArray® panels

Alexandre Mérieux, Chief Executive Officer, said: "Supported by strong momentum in the Americas and a good start in the Asia-Pacific region, we achieved organic growth of 11.5% in the first three months of the year. Backed by our solid first-quarter 2016 performance, we are continuing our drive to enhance operating efficiency in line with our strategic roadmap and our full-year objectives."

bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the three months ended March 31, 2016.

Sales

Consolidated sales rose to €489 million in the first three months of 2016 from €448 million in the year-earlier period. This represents growth of 9.1% as reported and includes a negative currency impact of around €7 million as well as the previously announced deconsolidation of bioTheranostics as of January 1, 2016. Organic growth (at constant exchange rates and scope of consolidation) represented 11.5% year-on-year, led by strong FilmArray® sales (for around 400 basis points), despite a weaker flu season that also began later than in the same period of 2015.